- TLDR Biotech
- Archive
- Page 3
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | January 1 - 4, 2026
🧬 Insilico Medicine’s long-awaited IPO hits the Hong Kong Stock Exchange - raises $296M for AI-driven drug discovery platform, BioMarin Pharmaceutical to acquire Amicus Therapeutics for $4.8 billion in all-cash deal, Sanofi to acquire Dynavax Technologies for $2.2B to gain hepatitis B vaccine Heplisav-B, Roche's Lunsumio (mosunetuzumab) subcutaneous formulation wins FDA approval for relapsed or refractory follicular lymphoma, Aktis Oncology files IPO for their radiopharmaceutical miniprotein radioconjugates for cancer treatment, Shionogi acquires Mitsubishi Tanabe Pharma's ALS drug Radicava for $2.5 billion, AbbVie + Suzhou Zelgen Biopharmaceuticals partner on trispecific DLL3 asset ZG006 - $100M upfront & $1.2B total w/biobucks, Boehringer Ingelheim's Jascayd wins FDA approval for progressive pulmonary fibrosis targeting phosphodiesterase 4B
Biotech & Pharma Updates | December 17 - 18, 2025
🧬 Novo Nordisk files CagriSema (cagrilintide/semaglutide) for FDA approval targeting amylin-GLP-1 pathways in obesity, Athira Pharma + Sermonix Pharmaceuticals partner on breast cancer drug lasofoxifene for $34.9M equity + $100M milestones, Insilico Medicine aims for $292M IPO on the Hong Kong Stock Exchange, AI-powered drug discovery and development platform, Novartis builds largest global R&D hub outside Switzerland in India with 9,000 employees, Orum Therapeutics raises $100M funding, degrader-antibody conjugates for cancer treatment, Syremis Therapeutics launches with $165M Series A to develop M1/M4 muscarinic drug rivaling BMS’s Cobenfy for schizophrenia
Biotech & Pharma Updates | December 16 - 17, 2025
🧬 Addition Therapeutics emerges from stealth with $100M to develop novel gene therapies for chronic + rare diseases, Merck & Co.'s Keytruda (pembrolizumab) plus Padcev hits Ph3 endpoints in perioperative muscle-invasive bladder cancer treatment, Boehringer Ingelheim + Galux partner on AI-driven precision protein design research using GaluxDesign platform, Alnylam Pharmaceuticals invests $250M to expand RNAi manufacturing facility using new enzymatic ligation technology, Cascade Pharmaceuticals raises $46M Series B for phase III trials and pipeline development, BMS + Harbour BioMed collaborate on multi-specific antibodies - $90M upfront + $1.035B milestones, Johnson & Johnson's Rybrevant Faspro (amivantamab) receives FDA approval as first subcutaneous EGFR-targeted non-small cell lung cancer therapy
Biotech & Pharma Updates | December 15 - 16, 2025
🧬 Genentech + Caris Life Sciences collaborate on AI-driven cancer target discovery with $25M upfront + $1.1B milestones, Link Cell Therapies debuts with $60M series A for logic-gated CAR-T platform, Allink Biotherapeutics raises $47M Series A extension to advance ADC clinical programs, Ambros Therapeutics launches with $125M Series A to advance Italian non-opioid pain drug neridronate, Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for $315M, Fosun Pharma acquires 53% stake in Green Valley Pharmaceuticals for $200M - reviving Alzheimer's drug GV-971, GSK's Exdensur (depemokimab) wins FDA approval for severe eosinophilic asthma treatment following Ph3 trials, Pfizer plans 15 obesity trials next year to replace $17 billion patent cliff revenue loss
Biotech & Pharma Updates | December 14 - 15, 2025
🧬 Chai Discovery raises $130M Series B for AI-powered drug design suite development, XOMA Royalty acquires Generation Bio for $4.29 per share plus contingent value rights, Novo Nordisk launches Ozempic in India - pricing lowest dose at $24 weekly for diabetes market, Link Cell Therapies raises $60M Series A to develop next-gen CAR-T therapies, Kyverna Therapeutics' miv-cel CAR-T therapy meets Ph2 endpoints for stiff person syndrome, Adaptive Biotechnologies + Pfizer partner on TCR platform for rheumatoid arthritis in up to $890M biobucks deal, Sanofi in-licenses Adel Therapeutics Alzheimer's antibody ADEL-Y01 for $80M upfront and up to $1.04B total deal value, FDA approves AstraZeneca and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) for first-line HER2-positive metastatic breast cancer
Biotech & Pharma Updates | December 11 - 14, 2025
🧬 William Blair predicts biotech sector will outperform 2021-24 bear markets in 2026 outlook, CIRM approves $160M funding for regenerative medicine research and clinical trials, Zealand Pharma seeks brain-targeting obesity treatment partners - explores shuttle technology collaborations, Tenaya Therapeutics raises $60M public offering to develop heart disease therapies, Sobi acquires Arthrosi Therapeutics for $950M upfront - adding gout treatment pozdeutinurad to pipeline, Anixa Biosciences' alpha-lactalbumin vaccine shows positive Ph1 results for triple-negative breast cancer prevention, Innovent Biologics' mazdutide (GLP-1/glucagon dual agonist) shows significant weight loss in Ph1b obesity trial in Chinese adolescents, FDA expands Johnson & Johnson's Akeega (abiraterone/niraparib) approval for BRCA2-mutated metastatic castration-sensitive prostate cancer
![The $4 Million Problem [Guest Post]](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=800,height=421,fit=scale-down,onerror=redirect/uploads/publication/thumbnail/5a180b8a-b34c-48db-a2ed-64c17f43d4d9/landscape_Screenshot_2025-11-27_at_10.21.52_PM.png)
Biotech & Pharma Updates | December 10 - 11, 2025
🧬 Zealand Pharma + OTR Therapeutics partner on metabolic disease therapeutics with $20M upfront + $2.5B biobucks, Amgen's Uplizna (inebilizumab) wins FDA approval for generalized myasthenia gravis targeting CD19-positive B cells, Xcell Biosciences + Culture Biosciences partner to advance cell therapy quality through AI and machine learning, Eli Lilly's retatrutide (triple hormone receptor agonist) achieves 26.6% weight loss in Ph3 obesity trial, Aukera Therapeutics emerges from stealth with CHF 4.5M ($5.63M) funding for neurological RAPTOR inhibitor development, Prolynx raises $70M Series A for longer-lasting obesity drugs with less frequent dosing, European legislators agree on major pharma policy overhaul reducing drug exclusivity periods + strengthening supply chains
Biotech & Pharma Updates | December 9 - 10, 2025
🧬 FDA approves Fondazione Telethon's gene therapy for Wiskott-Aldrich syndrome - first gene therapy approved from a non-profit sponsor, Formation Bio + Lynk Pharmaceuticals partner on TYK2 inhibitor LNK01006 with $605M total deal value, InduPro Therapeutics + Sanofi partner on bispecific PD-1 agonist for autoimmune disorders with undisclosed equity investment, Roche's giredestrant (oral SERD) shows 30% risk reduction in Ph3 early estrogen receptor-positive breast cancer trial, PsiThera raises $47.5M Series A for AI-designed oral drugs for immune conditions, Great Point Partners acquires majority stake in Lenis Group - specialty pharmaceutical distributor in Central and Eastern Europe, FDA finalizes guidance on promotional materials for biologics and biosimilars requiring accurate + non-misleading advertising
Biotech & Pharma Updates | December 8 - 9, 2025
🧬 Pfizer vaults another attempt towards an obesity pill by partnering with YaoPharma on Ph1 asset YP05002 - $150M upfront + $1.94B biobucks, Roche's Gazyvaro (obinutuzumab) wins EU approval for lupus nephritis treatment following Ph3 trial success, Cellular Origins raises $40M Series A for cell therapy manufacturing automation platform, Eli Lilly selects Alabama for $6B API facility to produce weight-loss pill orforglipron, Bora Pharmaceuticals + Corealis Pharma form strategic alliance for end-to-end oral solid dose development and production, Sidera Bio raises $109M Series A, developing obesity GLP-1/GIP/FGF21 triple agonist, BioNTech and Bristol Myers Squibb report positive Ph2 data for pumitamig in triple-negative breast cancer, Novartis' ianalumab hits Ph3 endpoints in immune thrombocytopenia
Biotech & Pharma Updates | December 7 - 8, 2025
🧬 Mirum Pharmaceuticals acquires Bluejay Therapeutics for $620M to gain hepatitis D drug brelovitug nearing Phase 3 results, Dr. Reddy's + Immutep partner on phase 3 immunotherapy eftilagimod alpha - $20M upfront + $349.5M biobucks, Biogen + Stoke Therapeutics' zorevunersen shows 82% seizure reduction in Dravet syndrome patients through 24 months, Dyne Therapeutics' zeleciment rostudirsen (z-rostudirsen) shows strong Ph1/2 results in Duchenne muscular dystrophy, Pan Cancer T raises €10M ($11.64M) funding for TCR-T cell therapy trial, China launches first private insurance formulary featuring drugs from big pharma, Singapore allocates $28.5 billion over five years for deep tech research including AI and biotechnology development
Biotech & Pharma Updates | December 4 - 7, 2025
🧬 German court grants Halozyme preliminary injunction halting Merck & Co.'s Keytruda SC launch activities over patent dispute, Immortal Dragons + Etheros partner on aging disease drugs targeting oxidative stress with fullerene derivatives, FDA approves Ayrmid's Omisirge (omidubicel-onlv) as first cell therapy for severe aplastic anemia treatment, FDA lifts partial clinical hold on Vanda Pharmaceuticals' motion sickness drug tradipitant following dispute resolution, Protara raises $75M public offering to fund TARA-002 clinical development program, Vertex's Casgevy (exagamglogene autotemcel) hits Ph3 goals in children with sickle cell disease and beta thalassemia, Pfizer's Hympavzi shows Ph3 success reducing bleeding in hemophilia A and B patients with inhibitors